vTv Therapeutics Inc. - (VTVT) News

vTv Therapeutics Inc. - (VTVT)

Today's Latest Price: $1.70 USD

0.04 (-2.30%)

Updated Oct 30 4:00pm

Add VTVT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter VTVT News Items

VTVT News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest VTVT News From Around the Web

Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 …

Benzinga | September 23, 2020

An In-Depth Look At vTv Therapeutics

Pity is the most agreeable feeling among those who have little pride and no prospects of great conquests."― Friedrich Nietzsche Today, we take an in depth look at a small developmental company that comes up from time to time in comments. The stock also sees large purchases of stock by...

The Insiders Forum on Seeking Alpha | September 16, 2020

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

HIGH POINT, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended…

GlobeNewswire | August 3, 2020

vTv Therapeutics' TTP399 successful in mid-stage type 1 diabetes study

VTv Therapeutics (VTVT) is up 45% premarket on the heels of results from the Phase 2 Simplici-T1 study evaluating TTP399 as an adjunct to insulin therapy in adults with type 1 diabetes.The results demonstrate that TTP399, a once-a-day pill, reduces HbA1c and improves time in range, without increasing hypoglycemia or any signal for adverse...

Seeking Alpha | June 15, 2020

Is vTv Therapeutics Inc (VTVT) A Good Stock To Buy?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | June 4, 2020

3 Biotech Stocks Under $3 With 200%-Plus Upside Potential

The healthcare sector took its place among the winners this year, rising 11%, compared to the S&P 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular. However, before making hasty decisions, it should be noted that these stocks are notoriously risky, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Understanding the volatile nature of the industry itself, we used TipRanks database to pinpoint exciting biotech plays that won’t break the bank. We found three trading for less than ...

Yahoo | May 12, 2020

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

HIGH POINT, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March…

GlobeNewswire | May 7, 2020

Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year?

Is (VTVT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research | March 12, 2020

vTv Therapeutics Inc. (VTVT) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT).

Zacks Investment Research | February 24, 2020

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C., Feb. 20, 2020 -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an.

Yahoo | February 20, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.5822 seconds.